Actually, LymPro is mentioned in the blog, but the main focus is on MANF. I had to re-read the blog to see this.

Quote:

---

We will be delivering the confirmatory AD results to the market very shortly, which in turn raises interesting prospects vis-a-vis our LymPro blood test for Alzheimer’s disease. When we first in-licensed LymPro, we had no idea that MANF could have an impact on aspects of the underlying pathophysiology of AD. However, with recently published data linking tau mis-folding to cell cycle dysregulation and amyloid aggregation, the prospect of MANF becoming the basis for new treatments in AD has become extremely interesting.

---